Erythema Nodosum-Like Rash After Sars-Cov-2 Vaccination: A Case Report

Herrera, Martin; West, Kathryn; Holstein, Heather

doi:10.1016/j.chest.2021.07.1261

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7,12 There have also been case reports of vaccine-associated EN with various COVID-19 vaccines. 13,14 Vaccineassociated EN is even more uncommon in children with our patient being only the third case reported in the literature 7,12 and the first case in a child less than 5 years of age. The pathogenesis of vaccine-related EN has yet to be established, with most study authors theorizing that the development of EN is secondary to the antigen of the infectious agent in the vaccines or a hypersensitivity reaction to adjuvant vaccine components that causes inflammation of the subcutaneous tissue due to immune complex deposition.…”

Section: Discussionmentioning

confidence: 65%

Erythema Nodosum in an Infant Associated With Meningococcal ACWY, Measles, Mumps, Rubella, and Pneumococcal Vaccines: A Case Report

Lee,

Abass

2023

Clin Pediatr (Phila)

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 65%

Erythema Nodosum in an Infant Associated With Meningococcal ACWY, Measles, Mumps, Rubella, and Pneumococcal Vaccines: A Case Report

Lee,

Abass

2023

Clin Pediatr (Phila)

View full text Add to dashboard Cite

“…Several cases of uncommon cutaneous manifestations of vaccines have been reported and are summarized in Supplementary Table 5 . 18 , 21 , 24 , 43 , 51 , 68 , 78 - 105 These include toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), skin necrosis, angioedema, edematous infiltrated plaques, Sweet syndrome, acute generalized exanthematous pustulosis, erythema multiforme (EM), erythema nodosum (EN), radiation recall dermatitis, papular acrodermatitis, cutaneous lichen planus (LP), new-onset and exacerbation of cutaneous lupus erythematosus (cLE), T-cell predominant cutaneous lymphoid hyperplasia, lichenoid reactions, pityriasis lichenoides et varioliformis Acuta (PLEVA), molluscum contagiosum, cutaneous mucormycosis at the injection site, livedo racemosa, fixed drug eruption (FDE), vulvar aphthae, purpura due to Evan’s syndrome, and dermatomyositis. New-onset psoriasis and vitiligo have also been reported.…”

Section: Narrative Review Of Common and Uncommon Cutaneous Manifestat...mentioning

confidence: 99%

Vesiculobullous and Other Cutaneous Manifestations of COVID-19 Vaccines: a Scoping and Narrative Review

Mahmood

Cyr

et al. 2023

J Cutan Med Surg

View full text Add to dashboard Cite

As coronavirus disease (COVID-19) vaccines continue to be administered, dermatologists play a critical role in recognizing and treating the cutaneous manifestations (CM) associated with the vaccines. Adverse cutaneous reactions of COVID-19 vaccines reported in the literature range from common urticarial to rare vesiculobullous reactions. In this study, we performed a (1) scoping review to assess the occurrences of vesicular, papulovesicular, and bullous CMs of COVID-19 vaccines and their respective treatments, and (2) a narrative review discussing other common and uncommon CMs of COVID-19 vaccines. Thirty-six articles were included in the scoping review, and 66 articles in the narrative review. We found that vesicular, papulovesicular, and bullous lesions are infrequent, reported mostly after the first dose of Moderna or Pfizer vaccines. Eleven of the 36 studies reported vesicular reactions consistent with activation or reactivation of the herpes zoster virus. Most vesicular and bullous lesions were self-limited or treated with topical corticosteroids. Other CMs included injection-site, urticarial or morbilliform reactions, vasculitis, toxic epidermal necrolysis, and flaring of or new-onset skin diseases such as psoriasis. Treatments for CMs included topical or oral corticosteroids, antihistamines, or no treatment in self-limited cases. Although most CMs are benign and treatable, the data on the effect of systemic corticosteroids and immunosuppressive therapies on the immunogenicity of COVID-19 vaccines is limited. Some studies report reduced immunogenicity of the vaccines after high-dose corticosteroids use. Physicians may consult local guidelines where available when recommending COVID-19 vaccines to immunosuppressed patients, and when using corticosteroids to manage the CMs of COVID-19 vaccines.

show abstract

mrna-1273

2021

Reactions Weekly

View full text Add to dashboard Cite

Erythema nodosum: case reportA 44-year-old woman developed erythema nodosum after receiving vaccination with mRNA-1273 for COVID-19 infection * . The woman, who had progressively worsening rash on her lower extremity, presented to the emergency department (ED). She had received the second dose of mRNA-1273 [Moderna; route and dosage not stated] vaccine. She developed rash 7 days after receiving the second vaccination dose and initially presented to her primary care physician. Following presentation in the ED, examinations showed stable vital signs. Physical examination was notable for multiple, tender, non-blanchable 6-8cm erythematous nodules on the bilateral calves and shins. No abnormalities were noted during laboratory examinations at the primary care physician. Her only notable finding was elevated C-reactive protein of 23.5 mg/L. Based on the symptoms and investigations, a diagnosis of erythema nodosum secondary to mRNA-1273 vaccination was considered.The woman was discharged on supportive care with unspecified non-steroidal anti-inflammatory drugs [outcome not stated].

show abstract

Erythema Nodosum-Like Rash After Sars-Cov-2 Vaccination: A Case Report

Cited by 5 publications

References 0 publications

Erythema Nodosum in an Infant Associated With Meningococcal ACWY, Measles, Mumps, Rubella, and Pneumococcal Vaccines: A Case Report

Erythema Nodosum in an Infant Associated With Meningococcal ACWY, Measles, Mumps, Rubella, and Pneumococcal Vaccines: A Case Report

Vesiculobullous and Other Cutaneous Manifestations of COVID-19 Vaccines: a Scoping and Narrative Review

mrna-1273

Contact Info

Product

Resources

About